Antiproliferative activity of cisplatin detected by CFSE in p53-proficient and p53-deficient cells

Paolo Ubezio, Monica Lupi, Giada Matera

Research output: Contribution to journalArticlepeer-review


We have previously developed experimental and data analysis procedures to measure the antiproliferative activity of drugs in continuously proliferating cancer cell lines using carboxyfluorescein diacetate succinimidyl ester (CFSE). The method was applied here to analyze the role of p53 in the effect of the anticancer drug cisplatin, distinguishing events occurring in the first generation of cells from those in the second and subsequent generations. A CFSE-loaded colon carcinoma cell line expressing functional wild-type p53 was treated for 1 with cisplatin in parallel with its p53-deficient counterpart, collecting frequency distributions of DNA and CFSE content up to 72 h after treatment. At a sublethal cisplatin concentration proliferation was temporarily inhibited but then the block was overcome and most cells were able to divide several times. The initial block was stronger in HCTp53-/- cells, resulting in a larger proportion of undivided cells at 24 h. This was confirmed and amplified at a higher, lethal concentration, where undivided G2M-blocked p53-deficient cells eventually died by non-apoptotic mechanisms, while p53-proficient cells avoided this with a less stringent block. This gave p53-proficient cells more time to repair and eventually decide on survival or apoptotic death before traversing the cycle into their second generation.

Original languageEnglish
Pages (from-to)847-859
Number of pages13
JournalImmunological Investigations
Issue number5-6
Publication statusPublished - Sep 2007


  • Cell division
  • Cell proliferation
  • CFSE
  • Cisplatin
  • Complexity
  • Drug effects
  • Flow cytometry

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Antiproliferative activity of cisplatin detected by CFSE in p53-proficient and p53-deficient cells'. Together they form a unique fingerprint.

Cite this